MCB Alert: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Metropolitan Bank Holding Corp. (NYSE: MCB) Investors with Significant Losses to Contact Firm

Metropolitan Bank Holding (MCB) saw Q2 earnings sharply disappoint (EPS $1.54 vs. ~$2.28 consensus), with credit loss provisions and write-downs driving the miss. The news also highlighted reserve adequacy concerns, including $14M in unexpected charge-offs (including $10M C&I) and additional legal-fee reimbursement falling short of prior “full recovery” messaging. Following the July 21 disclosures, MCB shares dropped nearly 9% in a single session, and a securities-law investigation is now underway focused on potentially misleading credit quality disclosures.

Analysis

This is less about the litigation headline and more about a credibility reset in credit underwriting. For a small bank, one or two surprise charge-offs can force a higher normalized provision rate, which hits price-to-book more than near-term EPS and can keep the stock discounted until management proves two clean quarters of loan migration. The immediate loser is MCB; the only potential winners are cleaner regional-bank names that can now trade at a modest relative premium for better credit transparency.

The next 1-3 month catalyst is the next earnings print and any further reserve build or criticized-loan disclosure. Tail risk is that the July disclosures were not isolated and the market is still underpricing a second leg of legacy C&I/HNW problems, which would pressure funding confidence and multiple. Contrarian view: the move may already embed a lot of bad news; if provisions normalize and no new nonperformers appear, the legal overhang alone should not permanently impair tangible book. There is no obvious direct read-through to FCD.UN.TO unless broader credit spreads widen materially.

Key Decisions for Investors

• Short MCB on any relief bounce into the next earnings window; target 10-15% downside if another reserve surprise hits, with a stop if criticized assets flatten and provisions step down materially.
• If options liquidity is adequate, buy 1-2 month MCB put spreads rather than outright puts to cap decay; catalyst is the next quarterly update and any amended disclosures.
• Pair trade: long KRE / short MCB at roughly beta-neutral size to isolate idiosyncratic credit-risk underperformance; thesis breaks if the issue proves fully contained and MCB regains book-value credibility.
• Watch item only: if the next quarter shows no incremental NPLs and charge-offs revert toward peer levels, cover shorts quickly — the litigation itself is not enough to justify a long-duration bear case.